Form 4: Processa Pharmaceuticals CFO James H. Stanker Reports Stock Transactions Following Reverse Stock Split

James H. Stanker, CFO of Processa Pharmaceuticals, reports the distribution of vested restricted shares and tax withholding following a 20-to-1 reverse stock split.

Summary

• On January 1, 2024, James H. Stanker, the Chief Financial Officer of Processa Pharmaceuticals, engaged in transactions involving the company's common stock.
• These transactions included the distribution of 1,675 vested restricted shares and the disposal of 518 shares for tax withholding at a price of $2.79.
• Following these transactions, Stanker directly owns 6,120 shares of Processa Pharmaceuticals common stock.
• The reported amounts have been adjusted to reflect a 20-to-1 reverse stock split of Processa Pharmaceuticals' common stock, which became effective on January 22, 2024.
• Stanker also holds 24,037 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may be interested in the insider transactions as they provide insight into management's perspective on the company's stock.
• The reverse stock split impacts the number of shares held by all shareholders.

Key Dates

Keywords

Form 4, Processa Pharmaceuticals, Stock Transactions, James H. Stanker, Reverse Stock Split, Restricted Stock Units, CFO